 Viking Therapeutics recently reported their Q2 earnings that publicized the company still has a robust cash position to support their imposing pipeline of metabolic and endocrine therapeutic candidates. VK2809 and VK0214 continue to move forward towards potentially being best-in-class products. Regrettably, VKTX remains stagnant with no indications that we see a major move in either direction. 